Doklady Biochemistry and Biophysics

, Volume 469, Issue 1, pp 273–276 | Cite as

Neuropeptide cycloprolylglycine increases the levels of brain-derived neurotrophic factor in neuronal cells

  • T. A. Gudasheva
  • K. N. Koliasnikova
  • T. A. Antipova
  • S. B. Seredenin
Biochemistry, Biophysics, and Molecular Biology

Abstract

It was shown for the first time that the endogenous cyclic dipeptide cycloprolylglycine (CPG) at concentrations of 10–7 and 10–3 M and piracetam at a concentration of 10–3 M increased the content of brainderived neurotrophic factor (BDNF) in the culture of neuronal cells in normal state and under conditions of glutamate and 6-oxydopamine neurotoxicity. This may indicate the possible involvement of BDNF in the mechanism of action of neuropeptide CPG and piracetam.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gudasheva, T.A., Boyko, S.S., Akparov, V.Kh., Ostrovskaya, R.U., Skoldinov, A.P., Rozantsev, G.G., Voronina, T.A., Zherdev, V.P., and Seredenin, S.B., FEBS Lett., 1996, vol. 391, pp. 149–152.CrossRefPubMedGoogle Scholar
  2. 2.
    Guan, J., Mathai, S., Harris, P., Wen, J.-Y., Zhang, R., Brimble, M., and Gluckman, P., Neuropharmacology, 2007, vol. 53, no. 6, pp. 749–762.CrossRefPubMedGoogle Scholar
  3. 3.
    Gudasheva, T.A., Vasilevich, N.I., Zolotov, N.N., Lezina, V.P., Rozenberg, S.G., Kravchenko, E.V., Ostrovskaya, R.U., Voronina, T.A., Rozantsev, G.G., and Skoldinov, A.P., Khim.-Farm. Zh., 1991, vol. 25, no. 6, pp. 12–16.Google Scholar
  4. 4.
    Gudasheva, T.A., Ostrovskaya, R.U., Trofimov, S.S., Voronina, T.A., Skoldinov, A.P., and Seredenin, S.B., Byull. Eksp. Biol. Med., 1999, vol. 116, no. 10, pp. 411–413.Google Scholar
  5. 5.
    Gudasheva, T.A., Konstantinopol’skii, M.A., Ostrovskaya, R.U., and Seredenin, S.B., Byull. Eksp. Biol. Med., 2001, vol. 131, no. 5, pp. 547–550.CrossRefGoogle Scholar
  6. 6.
    Seredenin, S.B., Gudasheva, T.A., Boiko, S.S., Kovalev, G.I., Voronin, M.V., and Yarkova, M.A., Byull. Eksp. Biol. Med., 2002, vol. 133, no. 4, pp. 417–419.CrossRefGoogle Scholar
  7. 7.
    Kolyasnikova, K.N., Gudasheva, T.A., Nazarova, G.A., Antipov, P.I., Nikolaev, S.V., Antipova, T.A., Voronina, T.A., and Seredenin, S.B., Eksp. Klin. Farmakol., 2012, vol. 75, no. 9, pp. 3–6.Google Scholar
  8. 8.
    Povarnina, P.Yu., Kolyasnikova, K.N., Nikolaev, S.V., Antipova, T.A., and Gudasheva, T.A., Byull. Eksp. Biol. Med., 2015, vol. 160, no. 11, pp. 600–603.Google Scholar
  9. 9.
    Ahmed, A.H. and Oswald, R.E.., J. Med. Chem., 2010, vol. 53, no. 5, pp. 2197–2203.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Jourdi, H., Hsu, Y.-T., Zhou, M., Qin, Q., Bi, X., and Baudry, M., J. Neurosci., 2009, vol. 29, no. 27, pp. 8688–8697.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Autry, A.E. and Monteggia, L.M., Pharmacol. Rev., 2012, vol. 64, no. 2, pp. 238–258.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Firstova, Yu.Yu., Dolotov, O.V., Kondrakhin, E.A., Dubynina, E.V., Grivennikov, I.A., and Kovalev, G.I., Eks. Klin. Farmakol., 2009, vol. 72, no. 6, pp. 6–9.Google Scholar
  13. 13.
    Goswami, P., Swarnkar, S., Harsoliya, M.S., Singh, S., Nath, C., and Sharma, S., J. Pharmacy Res., 2011, vol. 4, no. 6, pp. 1716–1719.Google Scholar
  14. 14.
    Towbin, H., Staehelin, T., and Gordon, J., Proc. Nat. Acad. Sci U. S. A., 1979, vol. 76, no. 9, pp. 4350–4354.CrossRefGoogle Scholar

Copyright information

© Pleiades Publishing, Ltd. 2016

Authors and Affiliations

  • T. A. Gudasheva
    • 1
  • K. N. Koliasnikova
    • 1
  • T. A. Antipova
    • 1
  • S. B. Seredenin
    • 1
  1. 1.Zakusov Research Institute of PharmacologyRussian Academy of Medical SciencesMoscowRussia

Personalised recommendations